Topics

Nonalcoholic Steatohepatitis Therapeutics in AsiaPacific Markets to 2024 Launch of NASHSpecific Premium Products and Rising Prevalence to Drive the Market [Report Updated: 03122018] Prices from USD $4396

15:44 EST 2 Dec 2019 | BioPortfolio Report Blog

Nonalcoholic Steatohepatitis Therapeutics in AsiaPacific Markets to 2024 Launch of NASHSpecific Premium Products and Rising Prevalence to Drive the Market


Summary


Nonalcoholic steatohepatitis NASH is the severe form of nonalcoholic fatty liver disease NAFLD, characterized by a buildup of fat in the liver. Globally, the NAFLD prevalence rate is estimated to be around 25% and a significant proportion of these people are progressing to NASH.


The disease is more frequently progressive and may lead to cirrhosis with complications of hepatocellular carcinoma, liver failure and liverrelated death or the requirement of liver transplantation, which is not always feasible. NASH is a major global healthcare problem as the number of NASH patients is increasing.


NASH has been gradually rising in the AsiaPacific region, owing to the growing prevalence of diabetes, obesity and metabolic syndromes, an aging population and increasingly Westernized lifestyles. Increasing risk factors will result in more people living with the condition and drive revenue growth. Patients with NAFLD and NASH are at increased risk of mortality as well as liver, cardiovascular and malignancyrelated death.


The poor longterm prognosis associated with NASH in particular has created a pressing need for improved therapeutic options. At present, there is no approved drug to treat NASH. Lifestyle modification is the initial approach to managing patients with NASH, and then pharmacological treatments such as vitamin E and pioglitazone are recommended as firstline drugs for biopsyproven NASH.


Significant unmet need exists for NASHspecific products that can treat patients with the condition. NASHspecific therapies, namely selonsertib, elafibranor, Ocaliva and saroglitazar, are in the pipeline for NASH.


Scope


The NASH AsiaPacific market will be valued at $102.6m in 2024, growing from $33.7m in 2017 at a CAGR of 17.2%.

How will the approval of NASHspecific therapies affect the market?

The NASH market has cheap, generic, offlabel drugs, making it a particularly difficult market to penetrate. What are the main barriers a new therapy faces when entering the NASH market?

How will the annual cost of therapy and market size vary between the five assessed AsiaPacific markets?

How will changes in risk factors such as population age, obesity, type 2 diabetes, NAFLD, metabolic syndrome and lifestyle influence the market?

The pipeline for NASH therapies is quite diverse with a range of molecule types and molecular targets.

Which molecular targets appear most frequently in the pipeline?

How have the latestage therapies performed in clinical trials?

The level of unmet need in the NASH market is significantly high. Will the pipeline drugs fulfill these unmet needs?

Various drivers and barriers will influence the market over the forecast period.

Licensing deals are the most common form of strategic alliance in NASH, with total deal values ranging from under $10m to over $300m.

How do deal frequency and value compare between target families and molecule types?

What were the terms and conditions of key licensing deals?


Reasons to buy


This report will enable you to:

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Visualize the composition of the NASH market in terms of the dominant therapies for each patient subset, along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the market.

Analyze the NASH pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

Understand the potential of latestage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

Predict NASH market growth in the five assessed AsiaPacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising latestage molecules to market growth.

Identify commercial opportunities in the NASH deals landscape by analyzing trends in licensing and codevelopment deals.

Original Article: Nonalcoholic Steatohepatitis Therapeutics in AsiaPacific Markets to 2024 Launch of NASHSpecific Premium Products and Rising Prevalence to Drive the Market [Report Updated: 03122018] Prices from USD $4396

NEXT ARTICLE

More From BioPortfolio on "Nonalcoholic Steatohepatitis Therapeutics in AsiaPacific Markets to 2024 Launch of NASHSpecific Premium Products and Rising Prevalence to Drive the Market [Report Updated: 03122018] Prices from USD $4396"

Quick Search

Relevant Topic

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...